ArQule Company Profile (NASDAQ:ARQL)

About ArQule (NASDAQ:ARQL)

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARQL
  • CUSIP: 04269E10
  • Web:
  • Market Cap: $79 million
  • Outstanding Shares: 71,171,000
Average Prices:
  • 50 Day Moving Avg: $1.13
  • 200 Day Moving Avg: $1.12
  • 52 Week Range: $0.92 - $1.68
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.78
  • P/E Growth: -0.53
Sales & Book Value:
  • Annual Revenue: $2.41 million
  • Price / Sales: 32.78
  • Book Value: $0.14 per share
  • Price / Book: 7.93
  • EBITDA: ($26,760,000.00)
  • Return on Equity: -213.36%
  • Return on Assets: -82.21%
  • Debt-to-Equity Ratio: 1.43%
  • Current Ratio: 4.33%
  • Quick Ratio: 4.33%
  • Average Volume: 156,277 shs.
  • Beta: 1.52
  • Short Ratio: 10.48

Frequently Asked Questions for ArQule (NASDAQ:ARQL)

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) posted its earnings results on Friday, August, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. During the same period in the previous year, the business posted ($0.07) earnings per share. View ArQule's Earnings History.

When will ArQule make its next earnings announcement?

ArQule is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for ArQule.

Who are some of ArQule's key competitors?

Who are ArQule's key executives?

ArQule's management team includes the folowing people:

  • Patrick J. Zenner, Independent Chairman of the Board
  • Peter S. Lawrence, President, Chief Operating Officer
  • Paolo Pucci, Chief Executive Officer, Director
  • Robert J. Weiskopf, Chief Financial Officer, Treasurer
  • Brian Schwartz M.D., Chief Medical Officer
  • Timothy C. Barabe, Independent Director
  • Susan L. Kelley M.D., Independent Director
  • Ronald M. Lindsay Ph.D., Independent Director
  • Michael D. Loberg Ph.D., Independent Director
  • William G. Messenger D. Min., Independent Director

Who owns ArQule stock?

ArQule's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (19.90%), BIOTECHNOLOGY VALUE FUND L P (19.90%) and Curbstone Financial Management Corp (0.15%). Company insiders that own ArQule stock include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Institutional Ownership Trends for ArQule.

Who bought ArQule stock? Who is buying ArQule stock?

ArQule's stock was bought by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp. Company insiders that have bought ArQule stock in the last two years include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Insider Buying and Selling for ArQule.

How do I buy ArQule stock?

Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ArQule stock can currently be purchased for approximately $1.11.

MarketBeat Community Rating for ArQule (NASDAQ ARQL)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ArQule (NASDAQ:ARQL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for ArQule (NASDAQ:ARQL)
Price Target History for ArQule (NASDAQ:ARQL)
Analysts' Ratings History for ArQule (NASDAQ:ARQL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50N/AView Rating Details
12/27/2015Royal Bank Of CanadaUpgradeBuyN/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for ArQule (NASDAQ:ARQL)
Earnings by Quarter for ArQule (NASDAQ:ARQL)
Earnings History by Quarter for ArQule (NASDAQ ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.11)N/AView Earnings Details
8/4/2017Q2 2017($0.11)($0.10)ViewN/AView Earnings Details
5/3/2017Q1 2017($0.11)($0.11)ViewListenView Earnings Details
3/7/2017Q4 2016($0.10)($0.10)$1.20 million$1.19 millionViewListenView Earnings Details
11/7/2016Q316($0.09)($0.08)$1.10 million$1.22 millionViewListenView Earnings Details
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.13)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ArQule (NASDAQ:ARQL)
2017 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ArQule (NASDAQ:ARQL)
Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 61.03%
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/7/2017Paolo PucciCEOBuy1,101$1.15$1,266.15View SEC Filing  
9/6/2017Paolo PucciCEOBuy16,397$1.15$18,856.55View SEC Filing  
9/5/2017Paolo PucciCEOBuy19,156$1.14$21,837.84View SEC Filing  
8/29/2017Paolo PucciCEOBuy300$1.05$315.00View SEC Filing  
8/28/2017Paolo PucciCEOBuy2,970$1.05$3,118.50View SEC Filing  
8/25/2017Paolo PucciInsiderBuy9,492$1.05$9,966.60View SEC Filing  
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ArQule (NASDAQ:ARQL)
Latest Headlines for ArQule (NASDAQ:ARQL)
Loading headlines, please wait.



ArQule (ARQL) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.